e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

3.855 +0.035 (+0.92%)

Streaming Delayed Price Updated: 3:56 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

October 26, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform ↗

October 17, 2022

Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments.

Via Benzinga

Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation ↗

October 06, 2022

Via Benzinga

Is Illumina Still the Gamechanger in Genomics Sequencing?

October 04, 2022

Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused

Via MarketBeat

Recap: Myriad Genetics Q1 Earnings ↗

May 05, 2022

Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For November 2, 2021 ↗

November 02, 2021

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022 ↗

October 06, 2022

Upgrades

Via Benzinga

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

September 28, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

What's Up With Myriad Genetics Shares Trading Higher Tuesday? ↗

August 03, 2021

Myriad Genetics, Inc. (NASDAQ:MYGN) shares are trading hig...

Via Benzinga

Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022

July 28, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Can Artificial Intelligence Predict Our Future Health? ↗

July 05, 2022

Thousands of financial investors and Wall Street pundits advise people daily about what economic trends are coming, what stocks are hot and what is on the upswing. Those same investors and banks...

Via Benzinga

40 Stocks Moving In Tuesday's Mid-Day Session ↗

May 31, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

On Wednesday, 73 stocks hit new 52-week lows.

Via Benzinga

Myriad Genetics's Earnings: A Preview ↗

May 04, 2022

Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Myriad...

Via Benzinga

77 Biggest Movers From Yesterday ↗

June 01, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate...

Via Benzinga

FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis ↗

April 20, 2022

The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...

Via Benzinga

AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer ↗

March 14, 2022

The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-...

Via Benzinga

Myriad Genetics, Inc (MYGN) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

MYGN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Myriad Genetics Insider Sold Over $None In Company Stock ↗

September 28, 2021

Nicole Lambert, Corporate Officer at Myriad Genetics (NASDAQ:MYGN), made a large insider sell on September 27, according to a new SEC filing. What Happened: A Form 4 filing from...

Via Benzinga

Topics Regulatory Compliance

4 Stocks Insiders Are Buying ↗

August 09, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...

Via Benzinga

75 Biggest Movers From Yesterday ↗

August 04, 2021

Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that the it has received approval for a...

Via Benzinga

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Myriad Genetics, inc (MYGN) Q2 2021 Earnings Call Transcript ↗

August 03, 2021

MYGN earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

48 Stocks Moving In Tuesday's Mid-Day Session ↗

August 03, 2021

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures...

Via Benzinga

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗

August 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Earnings Scheduled For August 3, 2021 ↗

August 03, 2021

Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy